• Zamawiaj do paczkomatu
  • Płać wygodnie
  • Obniżka
Rheumatoid Arthritis

Rheumatoid Arthritis

9780198566304
1 890,00 zł
1 795,50 zł Zniżka 94,50 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 1 795,50 zł
Ilość
Produkt niedostępny
Nakład wyczerpany (niedostępny u wydawcy)

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DPD lub Pocztę Polską. Kliknij po więcej szczegółów

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni. Kliknij po więcej szczegółów

Opis
Rheumatoid arthritis (RA) is a chronic inflammatory disease, which affects 1% of the worlds population. Patients with RA not only have a progressive and debilitating disease and severe functional impairment, but can also experience a reduced life expectancy due to frequent involvement of the major organ systems. This new edition of Rheumatoid Arthritis charts the profound changes in research and patient management that have taken place over the last 5 years. Developments inmolecular biology have dramatically increased insight into the inflammatory and destructive pathways of this complex disease. Over half a million patients have been successfully treated with biologic therapy and advances in imaging techniques have allowed increasingly early detection of disease onset.Rheumatoid factor is no longer the unchallenged gold standard autoantibody but has competition from the anti-citrulline antibodies. Environmental factors influencing both susceptibility and progression have been sought, and smoking has emerged as a powerful factor. Steady progress in genetics is finally being made and one day it may be possible to predict RA before onset of symptomatic disease. It is against this backdrop of dynamic developments that the new edition of Rheumatoid Arthritis publishes.
Szczegóły produktu
OUP Oxford
84418
9780198566304
9780198566304

Opis

Rok wydania
2006
Numer wydania
2
Oprawa
twarda
Liczba stron
594
Wymiary (mm)
227 x 284
Waga (g)
1985
  • Preface; Section 1; Etiology; Genetics of rheumatoid arthritis; Epidemiology and determinants of susceptibility; Microbes in the pathogenesis of rheumatoid arthritis; Experimental models for rheumatoid arthritis; Section 2; Mechanisms of inflammation; The role of macrophages in rheumatoid arthitis; The role of T lymphocytes in rheumatoid arthritis; The role of neutrophils in the pathogenesis of rheumatoid arthritis; The role of fibroblast-like synoviocytes in rheumatoid arthritis; The roles of B cells in rheumatoid arthritis; Innate immunity and immune complexes in rheumatoid arthritis; Angiogenesis and cell trafficking; Cytokine networks; Autoantibodies in rheumatoid arthritis; Mechanisms of fibroblast-mediated joint destruction; Pain mechanisms in rheumatoid arthritis; The stress system and the hypothalamic-pituitary adrenal (HPA) axis in rheumatoid arthritis; Section 3; Clinical Aspects; Examination of the synovium and synovial fluid; Clinical aspects of rheumatoid arthritis; Imaging in rheumatoid arthritis; Susceptibility, prognosis & mortality; Biomarkers for cartilage and bone in rheumatoid arthritis; Section 4; Drug Therapy; NSAIDS and analgesics; Systemic and intra-articular glucorticoids in rheumatoid arthritis; Methotrexate and Leflunomide; Gold, antimalarials, sulfasalazine, and other DMARDS; Combination therapy with synthetic DMARDs in the treatment of rheumatoid arthritis; Biologics in the treatment of rheumatoid arthritis; Section 5; Non-Drug Therapy; The impact of physiotherapy; Patient Education; Occupation therapy and assistive products and technology; Psychological and social aspects; Pain management; Health economics; Section 6; Surgical Therapy; Large joints and feet; The hand; The cervical spine; Section 7; Frontiers of Therapy; Design of trials involving clinical endpoints; Clinical trials with imaging and biomark endpoints; New biologics:: cytokines; New biologics:: T and B cell modulators; Inhibibition of proteolytic activity involved in cartilage breakdown; Signal transduction in rheumatic diseases; Mesenchymal stem cells in arthritis;
Komentarze (0)